154 results on '"Sarid, Nadav"'
Search Results
2. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis
3. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients
4. A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma
5. Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: Portrait of a rare clinical entity
6. Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study
7. Retrospective analysis of efficacy and safety of third-line chemotherapy for metastatic colorectal cancer among elderly patients receiving targeted therapy in early lines
8. Clinically Complex LRBA Deficiency Due to a Founder Allele in the Georgian Jewish Population
9. Lymphoproliferative disease detected by breast cancer screening
10. Absolute monocyte count trichotomizes chronic lymphocytic leukemia into high risk patients with immune dysregulation, disease progression and poor survival
11. High Response Rate for Treatment With Gemtuzumab Ozogamicin and Cytarabine in Elderly Patients With Acute Myeloid Leukemia and Favorable and Intermediate-I Cytogenetic Risk
12. An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy
13. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome
14. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study
15. Lower Patient Anxiety and Unchanged Levels of Adherence to Hemato-Oncologic Treatment in Response to New Measures to Reduce Hospital Exposure Risk to COVID-19
16. Toxicity and Efficacy of CAR-T in Patients with DLBCL Above the Age of 70 Years Compare to Younger Patients – a Matched Control Multi-Center Cohort Study
17. Efficacy and safety of cefepime: a systematic review and meta-analysis
18. Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model
19. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients
20. Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice
21. Acute myeloid leukemia with 11q23/MLL rearrangement after ‘FCR’ regimen for chronic lymphocytic leukemia
22. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience
23. Characteristics and outcomes of adults with cytomegalovirus‐associated thrombocytopenia: a case series and literature review
24. The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants
25. Radiotherapy in mantle cell lymphoma: A literature review
26. Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data
27. The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants
28. Continuing dilemmas in the management of lymphoma during pregnancy: review of a 10-point case-based questionnaire
29. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study
30. Facing erythrocytosis: Results of an international physician survey
31. ‘Language of lies’: Urgent issues and prospects in verbal lie detection research
32. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
33. 51 - Toxicity and Efficacy of CAR-T in Patients with DLBCL Above the Age of 70 Years Compare to Younger Patients – a Matched Control Multi-Center Cohort Study
34. Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center
35. CT findings are highly predictive for perforation in patients with diffuse large B-cell lymphoma involving the intestines
36. Treatment and prognosis of stage I follicular lymphoma in the modern era – does PET matter?
37. The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma
38. Reduced-dose ICE chemotherapy ± rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma
39. Comparison of the Low Toxicity Tecam Conditioning Regimen to BEAM in Patients with Lymphoma Requiring Autologous Stem Cell Transplantation
40. Dividing plasma cells in the cerebrospinal fluid of a patient with refractory multiple myeloma
41. CT findings are highly predictive for perforation in patients with diffuse large B-cell lymphoma involving the intestines.
42. Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?
43. Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study.
44. Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study
45. Paradoxical Immune Reconstitution Inflammatory Syndrome Associated With Rituximab-Containing Regimen in a Patient With Lymphoma
46. Reduced-dose ICE chemotherapy ± rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma.
47. Cefepime versus other beta-lactam antibiotics for the treatment of infections in non-neutropenic patients
48. Predictive value of TP53 fluorescencein situhybridization in cytogenetic subgroups of acute myeloid leukemia
49. Cefepime versus other beta-lactam antibiotics for the treatment of infections in non-neutropenic patients
50. Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.